Historical study quantities
Sermorelin dosing: the MD Sermorelin study ledger
These are quantities administered in named studies, each tied to a population and purpose. They cannot establish a personal treatment schedule.
Sermorelin dosage for children
The childhood treatment question was growth in diagnosed GH deficiency. The pediatric literature reviewed by Prakash and Goa reports 30 µg/kg subcutaneously at bedtime, with height-velocity gains over 12 months and extended follow-up reported to 36 months. The historical diagnostic test used a single intravenous 1 µg/kg dose to assess pituitary GH release.
Those two uses asked different questions, even within pediatrics. I distrust a lone number detached from the diagnostic or treatment task that produced it. The difference is especially consequential when a search for sermorelin dosage for kids is really a question about a child’s growth.
The multicenter childhood growth study provides a clinical result for the treatment setting. Its population remains essential to any discussion of sermorelin dosage for height growth.
Historical sermorelin dose chart
Each row describes a published investigation. The tesamorelin row retains its own compound name.
| Study setting | Quantity administered in the study | Observation period or purpose |
|---|---|---|
| Pediatric diagnostic use | Sermorelin 1 µg/kg, intravenous, single dose | Pituitary GH-release test |
| Pediatric GH-deficiency treatment | Sermorelin 30 µg/kg, subcutaneous, at bedtime | 12 months; extended follow-up reported to 36 months |
| Khorram adult study | [Nle27]GHRH(1-29)-NH2 10 µg/kg, subcutaneous, nightly | 16 weeks in older men and women |
| Vitiello adult study | Sermorelin ~14 µg/kg (~1 mg), subcutaneous, nightly | 5 months in older adults |
| Vittone adult study | GHRH(1-29) 2 mg, subcutaneous, nightly | 6 weeks in older men |
| Baker adult study | Tesamorelin 1 mg/day, subcutaneous | 20 weeks in adults with and without mild cognitive impairment |
I prefer this arrangement to a free-floating range. It makes the change of compound or population harder to overlook. None of these rows is a prescription for a reader.
Half-life and route
The historical prescribing-information summary reports peak plasma concentration 5-20 minutes after subcutaneous administration, approximately 6% absolute bioavailability, plasma clearance of 2.4-2.8 L/min and an 11-12 minute terminal elimination half-life in healthy adult volunteers.
The same clinical reference describes GH release peaking at 30-90 minutes and persisting 2-4 hours. The peptide’s disappearance and the hormone response therefore occupy different windows. I regard a schedule inferred from half-life alone as pharmacological guesswork.
The chronic studies above used the subcutaneous route; the diagnostic use was intravenous. Historical intranasal pilot work represents another research setting. Route changes cannot be read as interchangeable entries on the same chart.
A sermorelin dosing protocol for an individual
The trials describe protocols with eligibility criteria and observation periods. They supply no universal adult wellness regimen. In the tesamorelin trial, 17% of treated participants required dose adjustment, despite a specified research protocol.
For current U.S. patient care, a licensed clinician makes the prescribing decision for a compounded preparation, within the limits of state and treatment; a request may be refused. Compounded sermorelin has no FDA approval. The regulatory history explains how this differs from the former approved product.
Questions about an error or excessive exposure are addressed under sermorelin overdose. The study ledger provides no safe upper limit for an individual.